BRPI0508084A - método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo - Google Patents

método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo

Info

Publication number
BRPI0508084A
BRPI0508084A BRPI0508084-3A BRPI0508084A BRPI0508084A BR PI0508084 A BRPI0508084 A BR PI0508084A BR PI0508084 A BRPI0508084 A BR PI0508084A BR PI0508084 A BRPI0508084 A BR PI0508084A
Authority
BR
Brazil
Prior art keywords
treatment
meridamycin
salt
neurological disorder
disorder
Prior art date
Application number
BRPI0508084-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Edmund Idris Graziani
Kevin Pong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0508084A publication Critical patent/BRPI0508084A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0508084-3A 2004-03-02 2005-02-25 método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo BRPI0508084A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54943004P 2004-03-02 2004-03-02
PCT/US2005/006246 WO2005084673A1 (en) 2004-03-02 2005-02-25 Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents

Publications (1)

Publication Number Publication Date
BRPI0508084A true BRPI0508084A (pt) 2007-07-17

Family

ID=34919492

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508084-3A BRPI0508084A (pt) 2004-03-02 2005-02-25 método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo

Country Status (8)

Country Link
US (1) US20050197356A1 (https=)
EP (1) EP1720548A1 (https=)
JP (1) JP2007526312A (https=)
CN (1) CN1929837A (https=)
AU (1) AU2005219389A1 (https=)
BR (1) BRPI0508084A (https=)
CA (1) CA2556771A1 (https=)
WO (1) WO2005084673A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1720886A1 (en) * 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
MXPA06014080A (es) * 2004-06-03 2007-02-15 Wyeth Corp Agregado de genes biosinteticos para la produccion de un policetido complejo.
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
RU2008132779A (ru) 2006-03-07 2010-04-20 Вайет (Us) Аналоги меридамицина для лечения нейродегенеративных заболеваний
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US20100196355A1 (en) * 2007-01-29 2010-08-05 Wyeth Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
JP5681719B2 (ja) 2009-09-24 2015-03-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル タウ機能不全を伴う神経障害を処置するための新規な治療ターゲットとしてのｆｋｂｐ５２−タウ相互作用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) * 1993-02-02 1993-03-17 Sandoz Ltd Compounds
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US7041283B1 (en) * 2001-02-16 2006-05-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of using immunophilin binding drugs to improve integration and survival of neuronal cell transplants

Also Published As

Publication number Publication date
WO2005084673A1 (en) 2005-09-15
CA2556771A1 (en) 2005-09-15
CN1929837A (zh) 2007-03-14
US20050197356A1 (en) 2005-09-08
AU2005219389A1 (en) 2005-09-15
JP2007526312A (ja) 2007-09-13
EP1720548A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
BRPI0812889A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal.
SG155912A1 (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
WO2003096983A3 (en) Method of treating dyslipidemic disorders
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
SG170813A1 (en) New compounds
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
NZ608860A (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
PT2275097T (pt) Composições que incluem canabinoides para tratamento de náuseas, vómitos, émese, enjoo ou condições idênticas
WO2007089715A3 (en) Method for treatment of neuropathic pain
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
EA200400235A1 (ru) Комбинированная терапия для лечения рака
MX351062B (es) Proteinas de fusion para el tratamiento del snc.
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
SG166768A1 (en) Agonist anti-trkc antibodies and methods using same
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
EP1961447A3 (en) Treating depressive disorders with PKC activators

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.